The treatment regimen reduced the risk of developing distant metastases or death due to bladder cancer by 33%.

AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority ...

The phase 3 NIAGARA trial randomised 1,063 MIBC patients to receive Imfinzi plus neoadjuvant chemotherapy prior to bladder ...

AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered ...

AstraZeneca 4Q Revenues: $14.9 billion (+24%) 4Q Earnings: $1.5 billion (+56%) FY Revenues: $54.1 billion (+18%) FY Earnings: $7.0 billion (+18%) Comments: Oncology sales were $22.4 billion, up 21%.

AstraZeneca (NASDAQ:AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of muscle-invasive bladder cancer, or MIBC. The analysis showed ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered perioperatively in combination with neoadjuvant ...

We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer: Cambridge, UK Tuesday, February 4, 2025, 09:00 Hrs [IST] Astr ...